Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447954 · ClinicalTrials.gov registry record · Phase 2
A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
A Phase 2 study, sponsored by Neurotech Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00447954 is a Phase 2 study that has completed, run by Neurotech Pharmaceuticals. The registered enrollment target is 53 participants.
The verdict
NCT00447954, a Phase 2 study, has completed, sponsored by Neurotech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in participants with atrophic macular degeneration. This research is being done because there are no effective therapies for people with atrophic macular degeneration. Age-related macular degeneration (AMD) is a condition that affects the macula, the central part of the retina that we use for seeing details. There are two types of AMD, one is the wet type in which new blood vessels grow, also known as choroidal neovascularization (CNV), but the other is the dry type in which the healthy cells die, and that is the target of this study. This is called atrophic macular degeneration. The implant is a small capsule that contains human retinal pigment epithelium cells. These cells have been given the ability to make CNTF and release it through the capsule membrane into the surrounding fluid. In this study, two different CNTF dose levels will be used: a high dose and a low dose, as well as a sham surgery (or placebo) group.
Interventions
- OTHER Sham
- COMBINATION_PRODUCT High Dose NT-501 implant
- COMBINATION_PRODUCT Low Dose NT-501 implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2007-01-05 |
| Est. Completion | 2009-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00447954
The ClinicalTrials.gov registry entry for NCT00447954 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurotech Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham is the first listed.
NCT00447954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00447954 about?
NCT00447954 is a clinical study titled "A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration". The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in participants with atrophic macular degeneration. This research is being done because there are no effective therapies for people with atrophic macular degeneration. Age-related macular degeneration (AM...
What is the current status of trial NCT00447954?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2007-01-05. Estimated completion is 2009-05-11.
What interventions are being tested in trial NCT00447954?
The interventions under investigation include: Sham (OTHER), High Dose NT-501 implant (COMBINATION_PRODUCT), Low Dose NT-501 implant (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT00447954?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.